Extracellular Vesicle-Mediated Delivery of Mitochondrial Circular RNA MTCO2 Protects against Cerebral Ischemia by Modulating mPTP-Dependent Ferroptosis
Authors:
Open Access
- 1 January 2026
- journal article
- health science
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Abstract
Ischemic stroke remains a major cause of mortality and long-term disability, with few effective neuroprotective treatments currently available. Ferroptosis, an iron-dependent form of regulated cell death marked by lipid peroxidation, is increasingly recognized as a driver of neuronal damage. However, the mitochondrial mechanisms linking ischemia to ferroptosis remain poorly defined. Here, we identify circMTCO2, a mitochondria-encoded circular RNA (circRNA), as a novel endogenous modulator of neuronal ferroptosis. circMTCO2 expression is dynamically down-regulated following cerebral ischemia/reperfusion in vitro and in vivo. Mechanistically, circMTCO2 interacts with adenine nucleotide translocase 1 (ANT1), a key regulator associated with the mitochondrial permeability transition pore (mPTP), thereby inhibiting mPTP opening and suppressing mitochondrial reactive oxygen species release. Disruption of the binding site abolishes circMTCO2–ANT1 interaction and eliminates the protective effects of circMTCO2. To restore and enhance this intrinsic defense mechanism, we developed a dual-targeting extracellular vesicle system (RVG-EV mt-RNA ) capable of delivering circMTCO2 specifically to neuronal mitochondria. Systemic administration of RVG-EV mt-RNA decreased infarct volume, attenuated ferroptosis-associated injury, and improved neurological function in a mouse model of ischemic stroke, without inducing systemic toxicity. These findings establish circMTCO2 as a previously unrecognized mitochondrial circRNA that regulates ferroptosis by modulating mPTP activity and provide a proof of concept that organ-to-organelle circRNA delivery can be leveraged as a precision neuroprotective strategy for ischemic stroke.Keywords
Funding Information
- National Natural Science Foundation of China (82171269)
- Beijing Municipal Commission of Science and Technology (Z231100004823037)
- China Association for Science and Technology (YESS20220126)
- Capital Medical University Outstanding Young Talent Program (B2405)
This publication has 45 references indexed in Scilit:
- Exploring the Potential and Advancements of Circular RNA TherapeuticsExploration, 2025
- Engineered Exosome‐Based Senolytic Therapy Alleviates Stroke by Targeting p21+CD86+ MicrogliaExploration, 2025
- Synthetic Biology‐Based Engineering Cells for Drug DeliveryExploration, 2025
- Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and StrokesAdvanced Science, 2023
- Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS OutputCell, 2020
- Mitochondrial Genome-Derived circRNA mc-COX2 Functions as an Oncogene in Chronic Lymphocytic LeukemiaMolecular Therapy Nucleic Acids, 2020
- Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat StrokeCell, 2019
- Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectivesActa Pharmaceutica Sinica B, 2018
- Exosome Mediated Delivery of miR-124 Promotes Neurogenesis after IschemiaMolecular Therapy Nucleic Acids, 2017
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012